| Q53870892 | Challenges in the codevelopment of companion diagnostics. |
| Q54348234 | Comparison of HER2 status between surgically resected specimens and matched biopsy specimens of gastric intestinal-type adenocarcinoma. |
| Q36770491 | Correlation of human epidermal growth factor receptor 2 expression with clinicopathological characteristics and prognosis in gastric cancer |
| Q37468290 | HER2-positive gastric cancer |
| Q39470973 | High Tumor Vascular Endothelial Growth Factor Expression Is Associated With Poorer Clinical Outcomes in Resected T3 Gastric Adenocarcinoma |
| Q38776722 | High expression of EGFR predicts poor survival in patients with resected T3 stage gastric adenocarcinoma and promotes cancer cell survival |
| Q36824887 | Lauren classification and individualized chemotherapy in gastric cancer |
| Q53760324 | Overexpression of Pyruvate Kinase Type M2 (PKM2) Promotes Ovarian Cancer Cell Growth and Survival Via Regulation of Cell Cycle Progression Related with Upregulated CCND1 and Downregulated CDKN1A Expression. |
| Q36630742 | Prognosis significance of HER-2/neu overexpression/amplification in Chinese patients with curatively resected gastric cancer after the ToGA clinical trial |
| Q34585338 | Significance of human epidermal growth factor receptor 2 expression in colorectal cancer |
| Q41340207 | Targeted therapies for gastric cancer: failures and hopes from clinical trials |